The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma

European Cytokine Network

Volumn 11, Issue 4, 2000, Pages 546-551

  Barille S ^a   Bataille, R ^a   Amiot, M ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

Angiogenesis; Bone resorption; IL 6; Multiple myeloma; Soluble IL 6R ; STAT 3

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; DEXAMETHASONE; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MATRILYSIN; MEMBRANE PROTEIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; PARAPROTEIN; PROTEIN KINASE C; STAT PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN;

BONE MARROW; CELL PROLIFERATION; CELL SURVIVAL; GENE MUTATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW; BONE MARROW CELLS; BONE RESORPTION; CELL SURVIVAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-6; MACROMOLECULAR SUBSTANCES; MICE; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 0034517587     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Multiple myeloma
2. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders
3. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells
4. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
5. The Jak-STAT pathway: Cytokine signalling from the receptor to the nucleus
6. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
7. The function of the soluble interleukin-6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
8. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6
9. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice
10. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
11. Soluble receptors for cytokines and growht factors: Generation and biological function
12. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
13. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6
14. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines
15. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors
16. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells
17. CD130 rather than CD126 expression is associated with disease activity in multiple myeloma
18. Myeloma cells release soluble interleukin-6R-alpha in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage
19. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy
20. The soluble interleukin-6 receptor is generated by shedding
21. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
22. Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor
23. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
24. Identification and characterization of a pro-tumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloprotease
25. Metalloprotease-disintegrins: Modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding
26. Signaling through protein kinase C
27. The extended protein kinase C superfamily
28. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor
29. Interleukin-6 inhibits apoptosis of malignant plasma cells
30. Interleukin-6 prevents dexamethasone-induced myeloma cell death
31. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines
32. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
33. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
34. The Bcl-2 protein family: Arbiters of cells survival
35. L
36. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance
37. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation
38. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
39. L are co-regulated by IL-6 in human myeloma cells
40. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells
41. IL-6 upregulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway
42. The development of a model for the homing of multiple myeloma cells to human bone marrow
43. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures
44. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin
45. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
46. Vascular endothelial growth factor and interleukin-6 in paracrine tumorstromal cell interactions in multiple myeloma
47. Bone disease in multiple myeloma
48. Mechanisms of bone lesions in multiple myeloma and lymphoma
49. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma
50. Soluble IL-6 Ralpha upregulates IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells
51. Interleukin-6: An osteotropic factor?
52. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoclastic cells but not on osteoclast progenitors
53. Initiation of osteoclast bone resorption by interstitial collagenase
54. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption
55. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NFkappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone
56. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells
57. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
58. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
59. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis
60. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
61. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
62. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
63. Gelatinase A activity directly modulates melanoma cell adhesion and spreading
64. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
65. Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice
66. Long-term consequences of interleukin-6 overexpression in transgenic mice
67. Mouse plasmacytoma growth in vivo: Enhancement by interleukin-6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor
68. Biological effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
69. Interleukin-6 receptor superantagonists are potent inducers of human multiple myeloma cell death